Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1667521

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Antibiotics
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he plans to take steps to make (a) Cefiderocol and (b) Ceftazidimethose available on the NHS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	220
	answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE published guidance in August 2022 recommending both ceftazidime with avibactam and cefiderocol for treating severe drug-resistant gram-negative bacterial infections. This was as part of a project to test a new health technology evaluation process and payment model for antimicrobial products. NHS England has now issued contracts with the suppliers and cefiderocol and ceftazidime with avibactamare available for clinicians to prescribe in line with NICE’s recommendations.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 17:51:11 answering member 4423 label Biography information for Will Quince
	tabling member	4131 label Biography information for Jim Shannon

1667523

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Osteoporosis: Romosozumab
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department has a planned timescale for when romosozumab will be available in the NHS for the treatment of Osteoporosis.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	222
	answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance.</p><p>NICE published guidance in May 2022 recommending romosozumab for treating severe osteoporosis in people after menopause who are at high risk of fracture. Romosozumab is therefore available for clinicians to prescribe to NHS patients who meet the specified criteria, in line with NICE’s recommendations.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 10:25:40 answering member 4423 label Biography information for Will Quince
	tabling member	4131 label Biography information for Jim Shannon

1667530

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health: Working Hours
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of night work on (a) the level of risk of diagnosis with diabetes, (b) the level of risk of diagnosis with cardiovascular disease and (c) other health outcomes.
	tabling member constituency	Coventry North West
	tabling member printed	Taiwo Owatemi
	uin	523
	answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>We have made no such assessment.</p><p>The Major Conditions Strategy will set out how we intend to tackle conditions that contribute most to morbidity and mortality across the population in England which include cancers; cardiovascular disease, including stroke and diabetes; chronic respiratory diseases; dementia; mental ill health; and musculoskeletal conditions.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 17:52:28 answering member 4423 label Biography information for Will Quince
	tabling member	4779 label Biography information for Taiwo Owatemi

1667704

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ferric Maltol: Chipping Barnet
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that Ferric Maltol is available on prescription to people in Chipping Barnet constituency.
	tabling member constituency	Chipping Barnet
	tabling member printed	Theresa Villiers
	uin	104
	answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>Clinicians can prescribe any product on the National Health Service they consider necessary for the treatment of their patient unless it is listed in Schedules 1 or 2 to the NHS (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004. Ferric Maltol is not listed in Schedules 1 or 2; however, NHS guidance is that vitamins and minerals should not be routinely prescribed except for when a patient has a medically diagnosed deficiency. This includes those patients who may have a lifelong or chronic condition or have undergone surgery that results in malabsorption. Ferric Maltol, which may be used to treat iron deficiency, may therefore be prescribed to patients, including those in Chipping Barnet constituency, on that basis.</p><p>It is for the general practitioner or other responsible clinician to work with their patient and decide on the course of treatment, with the provision of the most clinically appropriate care for the individual always being the primary consideration. Clinicians are responsible for making prescribing decisions for their patients, considering best prescribing practice and the local commissioning decisions of their respective integrated care board.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 17:57:40 answering member 4423 label Biography information for Will Quince
	tabling member	1500 label Biography information for Theresa Villiers

1667958

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cystic Fibrosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether it is his Department's policy that people with cystic fibrosis will have access to (a) Orkambi, (b) Symkevi and (c) Kaftrio through the NHS.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	346
	answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>Orkambi, Symkevi and Kaftrio are currently available as treatment options for eligible National Health Service patients with cystic fibrosis, under the terms of a commercial agreement reached between NHS England and the manufacturer. This agreement has enabled the collection of data to inform a full appraisal of these medicines by the National Institute for Health and Care Excellence (NICE), which is currently underway.</p><p>NICE published draft guidance on 3 November 2023 which does not recommend Orkambi, Symkevi and Kaftrio for the treatment of cystic fibrosis. The draft guidance is now subject to a public consultation and NICE’s committee will carefully consider all evidence as well as comments received during the consultation in developing its final guidance, which is expected to be published on 20 March 2024. Patients already receiving these treatments will have continued access following the publication of NICE’s final guidance, regardless of the outcome.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 17:59:10 answering member 4423 label Biography information for Will Quince
	tabling member	4523 label Biography information for Catherine West

1668018

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Abiraterone
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will review the decision to reject the use of the drug Abiraterone to tackle prostate cancer.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	377
	answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that guides the National Health Service on funding new medicines, based on clinical and cost-effectiveness.. The NHS is legally required to fund medicines recommended by NICE, usually within 3 months of final guidance.</p><p>NICE has recommended abiraterone for the treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated and for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. NHS England funds abiraterone in line with NICE’s recommendations, ensuring access for eligible patients.</p><p>Abiraterone is not licensed for the treatment of non-metastatic prostate cancer and has therefore not been appraised by NICE for such use. NHS England is currently considering a clinical policy proposal for abiraterone as a treatment option for potential use in specific cases. The proposal is due to be discussed later this month, with potential stakeholder testing by January 2024, if supported.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 11:00:41 answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney

1666862

	registered interest
	date	24/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments: Innovation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answers of 16 October 2023 to Questions 200120, 200121, 200122 and 200123 on Medial Treatments: Innovation, which criteria within the MedTech Strategy Programme governance structures will be used to assess the range of initiatives.
	tabling member constituency	Dewsbury
	tabling member printed	Mark Eastwood
	uin	204055
	answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 08:59:38 answering member 4423 label Biography information for Will Quince
	tabling member	4807 label Biography information for Mark Eastwood

1666503

	registered interest
	date	23/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ovarian Cancer: Health Education
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will launch an awareness campaign on abdominal and urological symptoms of ovarian cancer.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	203763
	answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>NHS England is currently running a ‘Help us Help you’ campaign highlighting the abdominal and urological symptoms of cancer, including ovarian cancer, and addressing the barriers that stop people from accessing services in the National Health Service.</p><p>It encourages the public to contact their general practitioner if they're worried about symptoms, such as “tummy discomfort or diarrhoea that lasts for three weeks or more, or if they've seen blood in their pee even once”.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 08:50:31 answering member 4423 label Biography information for Will Quince
	tabling member	1409 label Biography information for Mr Gregory Campbell

1666537

	registered interest
	date	23/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Genomics: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 September 2023 to Question 198889 on Genomics: Health Services, if he will list the companies (a) involved in delivering and (b) that provided technology and products in support of the NHS Genomic Medicine Service.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	203889
	answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>It has not proved possible to reply to the hon. Member in the time available before prorogation.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 09:40:05 answering member 4423 label Biography information for Will Quince
	tabling member	4523 label Biography information for Catherine West

1666549

	registered interest
	date	23/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Young People
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure the Major Conditions Strategy reflects the (a) views and (b) needs of people with lived experience of cancer as a young adult.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	203755
	answer	answer is ministerial correction date of answer 25/10/2023 answer text <p>Cancer is a priority for this Government and the Department continues to take steps to demonstrate this. Childhood, young people’s and young adults’ cancers are included within the Department’s Major Conditions Strategy, which tackles contributions contributing most to morbidity and mortality.</p><p>While the Department cannot pre-empt its outcomes, the Major Conditions Strategy’s final report scheduled for early 2024 will draw on previous work, including submissions from childhood, young people and young adults’ cancer charities and stakeholders in response to our calls for evidence on cancer and on major conditions. The emphasis is on earlier diagnosis, better support to manage conditions, and improved coordination of treatment and care.</p><p>The Department is engaging with several stakeholders in the development of the Major Conditions Strategy including organisations that represent the needs and care of people with lived experience of cancer.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 203756 question first answered 25/10/2023 12:08:34 answering member 4423 label Biography information for Will Quince
	tabling member	481 label Biography information for Sir George Howarth